NCT02564263 2023-03-13KEYNOTE-181Merck Sharp & Dohme LLCPhase 3 Completed628 enrolled 27 charts 1 FDA
NCT02569242 2022-07-06Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal CancerOno Pharmaceutical Co. LtdPhase 3 Completed419 enrolled 20 charts 2 FDA